Patents by Inventor René Holm

René Holm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
    Patent number: 9227946
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: January 5, 2016
    Assignee: H. Lundbeck A/S
    Inventors: Andre Faldt, Rene Holm, Heidi Lopez de Diego
  • 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
    Patent number: 9125909
    Abstract: This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: September 8, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Andre Faldt, Arne Mork, Heidi Lopez de Diego, Rene Holm, Tine Bryan Stensbol
  • 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
    Patent number: 9125908
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: September 8, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Arne Mork, Tine Bryan Stensbol, Andre Faldt, Rene Holm, Heidi Lopez de Diego
  • 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
    Patent number: 8969355
    Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: March 3, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Andre Faldt, Rene Holm, Heidi Lopez de Diego
  • 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
    Publication number: 20140315921
    Abstract: This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.
    Type: Application
    Filed: July 9, 2014
    Publication date: October 23, 2014
    Inventors: Benny Bang-Andersen, Andre Faldt, Arne Mork, Heidi Lopez de Diego, Rene Holm, Tine Bryan Stensbol, Nicholas Moore
  • Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia
    Publication number: 20140194409
    Abstract: The present invention relates to 4-((1R,3S)-6-chloro-3-phenyl-indan-1yl)-1,2,2-trimethyl-piperazine and the salts thereof with activity at dopamine D1 and D2 receptors as well as the serotonin 5HT2 receptor for the treatment of diseases in the central nervous system in a once weekly dosing regime.
    Type: Application
    Filed: June 20, 2012
    Publication date: July 10, 2014
    Applicant: H. Lundbeck A/S
    Inventors: René Holm, Lone Bruun
  • 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
    Patent number: 8722684
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: May 13, 2014
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Andre Faldt, Arne Mork, Heidi Lopez de Diego, Rene Holm, Tine Bryan Stensbol, Nicholas Moore
  • Method for treating cognitive deficits
    Publication number: 20110207744
    Abstract: The invention relates to methods of treating cognitive dysfunction and improving cognitive functioning comprising the administration of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a pharmaceutically acceptable salt thereof to a patient in need thereof. Moreover the invention relates to an improved binder in a composition comprising 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine.
    Type: Application
    Filed: May 5, 2011
    Publication date: August 25, 2011
    Applicant: H. Lundbeck A/S
    Inventors: Christina Kurre Olsen, Rene Holm, Christine Kau, Birgitte Willumsen, Klaus Peter Hertel, Lone Bruun, Karina Krojer Soby
  • Oral Formulation
    Publication number: 20110178094
    Abstract: The invention relates to a pharmaceutical composition intended for oral administration comprising low doses of 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and to a composition comprising the compound.
    Type: Application
    Filed: October 1, 2009
    Publication date: July 21, 2011
    Applicant: H. LUNDBECK A/S
    Inventors: Rene Holm, Christine Kau, Birgitte Willumsen, Klaus Peter Hertel, Christina Kurre Olsen, Lone Bruun, Karina Krojer Soby
  • 1- [2- (2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
    Publication number: 20100297240
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: June 15, 2007
    Publication date: November 25, 2010
    Applicant: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Andre Faldt, Arne Mork, Heidi Lopez De Diego, Rene Holm, Tine Bryan Stensbol, Lone Munch Ringgaard, Michael J. Mealy, Michael Harold Rock, Jorgen Brodersen, Morten Jorgensen, Nicholas Moore
  • METHOD FOR TREATING COGNITIVE DEFICITS
    Publication number: 20090306092
    Abstract: The invention relates to methods of treating cognitive dysfunction and improving cognitive functioning comprising the administration of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a pharmaceutically acceptable salt thereof to a patient in need thereof. Moreover the invention relates to an improved binder in a composition comprising 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine.
    Type: Application
    Filed: May 7, 2009
    Publication date: December 10, 2009
    Applicant: H. Lundbeck A/S
    Inventors: Christina Kurre Olsen, Rene Holm, Christine Kau, Birgitte Willumsen, Klaus peter Hertel, Lone Bruun, Karina Krojer Soby
  • MODIFIED ABSORPTION FORMULATION OF GABOXADOL
    Publication number: 20090143335
    Abstract: The present invention relates to a pharmaceutical composition comprising gaboxadol or a pharmaceutically acceptable salt thereof and one or more inhibitors of PAT1 and/or one or more inhibitors of OAT. The present invention further relates to a pharmaceutical composition comprising from about 0.5 mg to about 50 mg gaboxadol or a pharmaceutically acceptable salt thereof, wherein the composition provides an in vivo plasma profile comprising a mean Tmax which is longer than about 20 minutes.
    Type: Application
    Filed: October 17, 2008
    Publication date: June 4, 2009
    Applicant: H. LUNDBECK A/S
    Inventors: Mie Larsen, Carsten Uhd Nielsen, Birger Brodin Larsen, Rene Holm